D2-40 as a diagnostic marker for pulmonary squamous cell carcinoma
K. H. Min, Y. C. Lee, S. J. Park, M. J. Chung, S. R. Kim, M. H. Lee, C. R. Chung, H. J. Han, W. S. Lee (Jeonju, Republic Of Korea)
Source: Annual Congress 2010 - Pathology of lung cancer
Session: Pathology of lung cancer
Session type: Thematic Poster Session
Number: 3260
Disease area: Thoracic oncology
Abstract Background: D2-40 monoclonal antibody, known as a reliable lymphatic endothelial cell marker, can be used for assessing lymphatic involvement by tumors. Recently, positive D2-40 reactivity has been reported in several tumors.Aims: We have evaluated the diagnostic utility of D2-40 and determined the relation between tumoral D2-40 positivity and clinicopathological parameters in non-small cell lung cancers (NSCLCs). Methods: We investigated 53 cases of NSCLCs (26 cases of squamous cell carcinoma (SCC), 19 cases of adenocarcinoma (AC), 4 cases of large cell carcinoma, 2 cases of sarcomatoid carcinoma, and 2 cases of carcinoid tumor) for the determination of D2-40 positivity on tumor cells in diagnostic tissue specimens using immunostaining method.Results: Positive D2-40 reactivity on tumor cells of diagnostic specimens was more frequently seen in patients with SCC (11 of 26, 42.3%) than in patients with AC (1 of 19, 5.3%; P=0.006). The malignant cells in cases of the large cell carcinoma, sarcomatoid carcinoma, and carcinoid tumor were negative for D2-40. In the cases of patients with surgically resected NSCLCs, the results of D2-40 positivity were very similar between diagnostic tissue specimens and surgically resected specimens. There was no significant association between tumoral D2-40 positivity and clinicopathological parameters, including tumor differentiation, clinical T stage, clinical N stage, clinical M stage, and survival in NSCLCs, even in subgroup of SCC.Conclusions: These results suggest that D2-40 reactivity on tumor cells can be used as a novel diagnostic marker for pulmonary SCC, even in small biopsy specimens.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. H. Min, Y. C. Lee, S. J. Park, M. J. Chung, S. R. Kim, M. H. Lee, C. R. Chung, H. J. Han, W. S. Lee (Jeonju, Republic Of Korea). D2-40 as a diagnostic marker for pulmonary squamous cell carcinoma. Eur Respir J 2010; 36: Suppl. 54, 3260
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Angiogenic squamous dysplasia: highly associated with squamous cell lung carcinoma Source: Annual Congress 2006 - Biological features, lung function and treatment of lung cancer Year: 2006
Bilateral squamous cell carcinoma Source: Annual Congress 2008 - Various thoracic tumours and interesting cases Year: 2008
Karyometric analysis of squamous metaplasia, dysplasia and squamous cell carcinoma of the lung Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement Source: Eur Respir J 2007; 30: 21-26 Year: 2007
Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma Source: Eur Respir J 2016; 47: 938-946 Year: 2016
COX-2 expression during early lung squamous cell carcinomas oncogenesis Source: Eur Respir J 2005; 26: Suppl. 49, 456s Year: 2005
Borderline early squamous cell lung cancer Source: ISSN=ISSN 1810-6838, ISBN=, page=157 Year: 2004
Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis Source: Eur Respir J 2008; 31: 854-859 Year: 2008
The value of AXL expression in squamous cell carcinoma of the lung: relationship with clinicopathological parameters. Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
Comparing LYVE-1 and D2-40 expression in small cell lung carcinomas (SCLC); association with clinical parameters and lymphatic invasion Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011
Karyometric analysis of bronchioloalveolar carcinoma (BAC) and adenocarcinoma of the lung Source: Eur Respir J 2006; 28: Suppl. 50, 91s Year: 2006
Pathology and immunohistochemistry of lung cancer Source: Eur Respir Mon; 2009: 44: 15–35 Year: 2009
Prognostic value of three-microRNA expression profile in early stage squamous cell lung cancer (SqCLC) Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer Year: 2010
COPD is a risk factor for squamous cell histotype in smokers who develop nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 361s Year: 2003
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006
An analysis of mRNA and long non-coding RNA (lncRNA) expression during the progression from pre-invasive lesions (PL) to invasive squamous cell carcinoma (SqCC) of the bronchus Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013
Large cell neuroendocrine carcinoma of the lung: Experience with 20 resected cases Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003